Core Viewpoint - Savara Inc. (NASDAQ: SVRA) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its drug MOLBREEVI, which is intended for the treatment of pulmonary alveolar proteinosis [3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 4, 2024, to May 23, 2025 [3]. - Allegations include that Savara failed to disclose critical information about MOLBREEVI's chemistry, manufacturing, and controls, leading to doubts about FDA approval [3]. - The complaint suggests that the delay in regulatory approval could necessitate Savara to raise additional capital [3]. Group 2: Shareholder Actions - Shareholders who purchased SVRA shares during the class period are encouraged to register for the class action and may seek lead plaintiff status [1][4]. - The deadline for shareholders to register is November 7, 2025, and there is no cost to participate [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Group 3: Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action. ...

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Group 1: Allegations and Company Performance - The complaint alleges that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), specifically that it lacked sufficient details on chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - Following the announcement of a refusal to file (RTF) letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [3]. Group 2: Legal Proceedings and Participation - Shareholders may be eligible to participate in the class action against Savara Inc., with the option to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - Savara, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product candidate, MOLBREEVI, and its Biologics License Application (BLA) submission to the FDA [1][4]. Company Overview - Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases [3]. - The company's lead product candidate is MOLBREEVI (molgramostim), an inhaled granulocyte-macrophage colony-stimulating factor [3]. - In December 2024, Savara began a rolling submission of a BLA to the FDA for MOLBREEVI to treat aPAP [3]. Legal Issues - The class action lawsuit alleges that Savara made false or misleading statements and failed to disclose critical information about the MOLBREEVI BLA, including insufficient data on chemistry, manufacturing, and controls [4]. - The lawsuit claims that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay the submission timeline and necessitate additional capital raising [4]. - On May 27, 2025, Savara announced it received a refusal to file (RTF) letter from the FDA, stating the BLA was not sufficiently complete for review, leading to a more than 31% drop in share price [5].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). Savara investors have until November 7, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE. ...

LOS ANGELES--(BUSINESS WIRE)---- $SVRA--SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. and certain officers for alleged violations of federal securities laws during the Class Period from March 7, 2024, to May 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Savara securities during the specified Class Period [2]. - The complaint alleges that the defendants made materially false and misleading statements regarding the company's business and operations, particularly concerning the MOLBREEVI Biologics License Application (BLA) [3]. - Specific allegations include the lack of sufficient information regarding MOLBREEVI's chemistry and manufacturing, the unlikelihood of FDA approval in its current form, and the potential need for Savara to raise additional capital due to delays in regulatory approval [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Savara have until November 7, 2025, to request appointment as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. and certain officers for alleged violations of federal securities laws during the Class Period from March 7, 2024, to May 23, 2025, seeking damages for affected investors [1][6]. Company Overview - Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its lead product candidate being MOLBREEVI (molgramostim), currently in a Phase 3 clinical trial for autoimmune pulmonary alveolar proteinosis (aPAP) [4]. - The company has claimed it is "sufficiently capitalized" through 2026 or into the second half of 2027 based on investments in MOLBREEVI and its fiscal discipline [4]. Regulatory Developments - In December 2024, Savara began a rolling submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI, expecting to complete the submission by the end of Q1 2025 [5]. - The BLA submission must include detailed information regarding MOLBREEVI's chemistry, manufacturing, and controls (CMC) [5]. Allegations in the Lawsuit - The lawsuit alleges that Savara's executives made materially false and misleading statements about the company's business and prospects, including claims about the sufficiency of the BLA and the likelihood of FDA approval [6]. - Specific allegations include that the BLA lacked sufficient information regarding CMC, making FDA approval unlikely in its current form [6]. Market Reaction - Following the announcement of a refusal to file letter from the FDA on May 27, 2025, Savara's stock price fell by $0.90, or 31.69%, closing at $1.94 per share [7][9]. - Analysts, such as Guggenheim, revised their price target for Savara from $9.00 to $8.00, predicting that the company may not be profitable until 2028 and may need to raise additional capital [8]. Financial Updates - After the Class Period, Savara announced on August 13, 2025, that it plans to resubmit the MOLBREEVI BLA in December 2025, contrary to previous statements about completing the submission in Q1 2025 [10].

SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Savara Inc. (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company’s lead product candidate is MOLBREEVI (also referred to as “molgramostim”), an inhaled granulocyte-macrophage colony-stimulating (“GM-CSF”) factor. For ...

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, which led to significant investor losses during the class period from March 7, 2024, to May 23, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Savara securities during the specified class period [2]. - Investors have until November 7, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that Savara did not disclose that the MOLBREEVI BLA lacked sufficient information, making FDA approval unlikely [4]. Group 2: Impact on Stock Price - On May 27, 2025, Savara announced it received a refusal to file letter from the FDA regarding the MOLBREEVI BLA, causing the stock price to drop by $0.90 per share, or 31.69%, closing at $1.94 per share [5]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors and encourages those who suffered losses to contact them for more information [6][7].